Anthony Hughes is senior reporter, equities, for IFR where he covers developments in US equity capital markets. He previously worked as a financial reporter and columnist for the Australian Financial Review and, prior to that, as investment editor at the Sydney Morning Herald.
Abbott Laboratories has sold more than 60% of its remaining stake in EpiPen maker Mylan in a US$1.7bn unregistered block trade via Morgan Stanley, one of the largest-ever commitments in this format.
Keysight Technologies launched a US$400m marketed equity raise late Monday, its first as an independent entity since being spun off from Agilent Technologies in 2014.
The painful decline in the prospects and share price of Valeant Pharmaceuticals International has proved too much to bear for its most ardent supporter, billionaire hedge fund activist Bill Ackman.